Abstract 1152
Background
This study was carried out as randomized-controlled, longitudinal interventional to determine whether there was a difference between the mean scores of compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) after applying the short-term and long-term ‘Compassion Fatigue Resiliency Program’ for nurses working in the field of oncology-hematology.
Methods
The sample of the study consisted of oncology-hematology nurses working in two private hospitals, one university hospital. Hospitals were randomly assigned to experiment I (n:34), experiment II (n: 49) and control groups (n: 42). Short-term (two days, five hours per day) program implemented to experiment I, long-term (five weeks, 2 hours a week) program implemented to experiment II and no any intervention implemented to control group. Measurements were made pre-intervention, post-intervention, third month, sixth month and first year. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Primary research hypotheses were tested with multilevel models (MLM).
Results
There was no statistically significant difference between the mean scores of CF, BO, PS and PR of the nurses in the short-term, long-term and control groups. The mean compassion satisfaction score of the nurses in the short-term and long-term education group was statistically significantly higher than in the control group. The mean CS scores of the nurses in both the short and long-term education groups were statistically significantly higher in the sixth month and first year follow-up measurements than in the pre-intervention period.
Conclusions
In this study, considering the effects of long-term and short-term education on CF, BO, CS, perceived stress and PR of nurses, it can be said that these two educations have the same effect on CS. It is the first study with randomized-controlled method, including the follow-up of up to a year. Doing new studies that are revealing the effect of this education can be suggested.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract